TJ Biopharma Co., Ltd.
Clinical trials sponsored by TJ Biopharma Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug targets Life-Threatening immune storm in rheumatic patients Results expected Dec 2026 (estimated)
-
New drug targets Life-Threatening immune storm in rheumatic patients
Disease control Recruiting nowThis phase 3 trial tests a drug called plonmarlimab in 30 adults with a severe immune overreaction (macrophage activation syndrome) linked to rheumatic diseases that hasn't responded to prior treatment. Participants receive weekly IV infusions for 8 weeks. The main goal is to see…
Phase 3 • Sponsor: TJ Biopharma Co., Ltd. • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New IV drug aims to tame gout flare pain in hours
Symptom relief Recruiting nowThis Phase 2 trial tests punarlimab, a new IV drug, against a standard steroid injection for quick relief of acute gouty arthritis pain. About 170 adults with frequent gout flares will receive a single dose and report their pain levels over 72 hours. The goal is to see if punarli…
Phase 2 • Sponsor: TJ Biopharma Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 12:04 UTC